Literature DB >> 30980562

Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Solène M Laville1, Bénédicte Stengel1, Ziad A Massy1,2, Sophie Liabeuf3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30980562      PMCID： PMC6533517          DOI： 10.1111/bcp.13924

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  20 in total

1.  Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Authors:  Solène M Laville; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335

2.  Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!

Authors:  Lisa K Stamp; Daniel F B Wright; Nicola Dalbeth
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

3.  A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.

Authors:  Lisa K Stamp; Peter T Chapman; Murray L Barclay; Anne Horne; Christopher Frampton; Paul Tan; Jill Drake; Nicola Dalbeth
Journal:  Ann Rheum Dis       Date:  2017-03-17       Impact factor: 19.103

4.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

5.  Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study.

Authors:  Seoyoung C Kim; Craig Newcomb; David Margolis; Jason Roy; Sean Hennessy
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-04       Impact factor: 4.794

6.  An open-label, 6-month study of allopurinol safety in gout: The LASSO study.

Authors:  Michael A Becker; David Fitz-Patrick; Hyon K Choi; Nicola Dalbeth; Chris Storgard; Matt Cravets; Scott Baumgartner
Journal:  Semin Arthritis Rheum       Date:  2015-05-21       Impact factor: 5.532

7.  Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.

Authors:  Chien-Yi Yang; Chi-Hua Chen; Shin-Tarng Deng; Chi-Shan Huang; Yu-Jr Lin; Yi-Ju Chen; Chun-Ying Wu; Shuen-Iu Hung; Wen-Hung Chung
Journal:  JAMA Intern Med       Date:  2015-09       Impact factor: 21.873

8.  Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases.

Authors:  Yi-Chun Chen; Hsien-Ching Chiu; Chia-Yu Chu
Journal:  Arch Dermatol       Date:  2010-08-16

Review 9.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228
View more
  1 in total

1.  Reply to "Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!" by Stamp et al.

Authors:  Solène M Laville; Bénédicte Stengel; Ziad A Massy; Sophie Liabeuf
Journal:  Br J Clin Pharmacol       Date:  2019-04-13       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.